

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 March 2006 (30.03.2006)

PCT

(10) International Publication Number  
**WO 2006/034317 A3**

(51) International Patent Classification:

A61K 31/445 (2006.01) C07D 403/04 (2006.01)  
A61K 31/404 (2006.01) C07D 405/04 (2006.01)  
C07D 209/42 (2006.01) C07D 409/04 (2006.01)  
C07D 401/04 (2006.01) C07D 413/04 (2006.01)  
C07D 401/06 (2006.01)

(21) International Application Number:

PCT/US2005/033752

(22) International Filing Date:

21 September 2005 (21.09.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/611,761 21 September 2004 (21.09.2004) US  
60/695,454 30 June 2005 (30.06.2005) US

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KERNS, Jeffrey, K.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **LINDENMUTH, Michael** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **LIN, Xichen** [CN/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **NIE, Hong** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US). **THOMAS, Sonia, M.** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US).

(74) Agents: **MADDEN, Laura, K.** et al.; Glaxosmithkline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King Of Prussia, PA 19406-0939 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:


- with international search report

(88) Date of publication of the international search report:

19 April 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS



(1)

(57) Abstract: The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (1): where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK $\beta$ ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

WO 2006/034317 A3

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/33752

## A. CLASSIFICATION OF SUBJECT MATTER

IPC: A61K 31/445( 2006.01),31/404( 2006.01);C07D 209/42( 2006.01),401/04( 2006.01),401/06( 2006.01),403/04( 2006.01),405/04( 2006.01),409/04( 2006.01),413/04( 2006.01)

USPC: 514/235.2,316,323;544/129,364;546/187,201

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/235.2, 255, 316, 323; 544/129, 364; 546/187, 201

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X --- P, Y	WO 2005/067923 A1 (BALDWIN et al.) 28 July 2005 (28.07.2005), see entire document especially pages 99, 107-108, 110-142 examples.	1-4, 13-25 ----- 5-12
Y	WERMUTH C. G. The Practice of Medicinal Chemistry, Academic Press, (1996), pages 203-214, see entire document.	5-12



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

05 October 2006 (05.10.2006)

Date of mailing of the international search report

29 NOV 2006

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Celia Chang

Telephone No. 571-272-1600

*F. Roberts for*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US05/33752

### BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-8, 10-25 when V is sulfonylpiperidine and claim 9, drawn to piperidinyl indoles, composition and method of use.

Group II, claims 1-8, 10, 13-25 when V is pyrrolidine and remaining compounds (not encompassed by group I) of claims 11-12, drawn to pyrrolidinyl indoles, composition and method of use.

Group III, claims 1-8, 13-25 when V is piperazine and remaining compounds (not encompassed by groups I and II), drawn to piperazinyl indoles, composition and method of use.

Group IV, claims 1-8, 13-25 the remaining compounds not encompassed by groups I, II or III, drawn to various core compounds, composition and method of use.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features as to form a single inventive concept.

**PCT Rule 13.1** states that the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention").

**PCT Rule 13.2** states that the unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features.

Annex B, **Part 1(a)**, indicates that the application should relate to only one invention, of if there is more than one invention, inclusion is permitted if they are so linked to form a single general inventive concept.

Annex B **Part 1(b)**, indicates that "special technical features" means those technical features that as a whole define a contribution over the prior art.

Annex B **Part 1(c)**, further defines independent and dependent claims. Unity of invention only is concerned in relation to independent claims. Dependent claims are defined as a claim that contains all the features of another claim and is in the same category as the other claim. The category of a claim refers to the classification of claims according to subject matter e.g. product, process, use, apparatus, means, etc.

Annex B **Part 1(e)**, indicates that the permissible combinations of different categories of claims. **Part 1(e)I**, states that inclusion of an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of the said product, and an independent claim for a use of the said product is permissible.

Annex B, **Part 1(f)**, indicates the "Markush practice" of alternatives in a single claim. **Part 1(f)I**, indicates the technical relationship and the same or corresponding special technical feature is considered to be met when (A) all alternatives have a common property or activity, and (B) a common structure is present or all alternatives belong to a recognized class of chemical compounds. Further defining (B), Annex B, **Part 1(f)(i-iii)**, the common structure must; a) occupy a large portion of their structure, or b) the common structure constitutes a structurally distinctive portion, or c) where the structures are equivalent and therefore a recognized class of chemical compounds, each member could be substituted for one another with the same intended result. That is, with a common or equivalent structure, there is an expectation relationship and the corresponding special technical feature result from a common (or equivalent) structure that is responsible for the common activity (or property). **Part 1(f) iv**, indicates that when all alternatives of a

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US05/33752

Markush grouping can be differently classified, it shall no, take alone, be considered justification for finding a lack of unity. **Part 1(f)v**, indicates that

"When dealing with alternatives, if it can be shown that at least *one* Markush alternative is not novel over the prior art, the question of unity of invention shall be reconsidered by the examiner"

In the instant case, at least one Markush alternative is not novel because prior art by Baldwin et al. CA 143:172754 RN 760626-02-4, 860626-60-4, 860627-57-2 anticipated compounds of group IV, thus the lacking of unity of invention has been demonstrated.

Continuation of B. FIELDS SEARCHED Item 3:

CAS--structure

East/West--image subclasses

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/33752

### Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 9 in its entirety, 1-8, 10-25 in part V is sulfonylpiperidine

- Remark on Protest**
- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐